U.S. Logistics Stock News

The most recent earnings report from Permian Resources Corporation ( NYSE:PR ) was disappointing for shareholders...

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) defied analyst predictions to release its quarterly results, which were ahead of...

We note that the X4 Pharmaceuticals, Inc. ( NASDAQ:XFOR ) CFO, Treasurer & Corporate Secretary, David Kirske, recently...

It's been a good week for Kura Oncology, Inc. ( NASDAQ:KURA ) shareholders, because the company has just released its...

Readers hoping to buy Energizer Holdings, Inc. ( NYSE:ENR ) for its dividend will need to make their move shortly, as...

GrowGeneration Corp. ( NASDAQ:GRWG ) just released its latest quarterly results and things are looking bullish. It...

Unsurprisingly, Paycom Software, Inc.'s ( NYSE:PAYC ) stock price was strong on the back of its healthy earnings...

The market was pleased with the recent earnings report from Amcor plc ( NYSE:AMCR ), despite the profit numbers being...

For investors watching Alnylam Pharmaceuticals (ALNY), the latest HELIOS-B Phase 3 analyses of vutrisiran and reaffirmed transthyretin, or TTR, franchise revenue guidance have put fresh attention on how clinical evidence and commercial execution intersect for this stock. See our latest analysis for Alnylam Pharmaceuticals. These HELIOS-B data and reaffirmed TTR guidance arrive after a period where the share price has fallen 26.7% year to date on a share price basis, even as the 5 year total...

Earlier this month, Regeneron Pharmaceuticals received U.S. Food and Drug Administration approval for Otarmeni, the first gene therapy for genetic hearing loss caused by OTOF gene variations, using a viral vector to deliver a working OTOF gene directly into the cochlea. This approval not only introduces a new option for patients with Otoferlin-related hearing loss, but also underscores Regeneron’s progress in applying its genetic medicine capabilities to real-world treatments. We’ll now...

NWPX Infrastructure (NWPX) is back in focus after a first quarter 2026 earnings beat, with EPS of $1.08 versus forecasts of $0.59, a record Water Transmission Systems backlog, and strong stock price momentum. See our latest analysis for NWPX Infrastructure. The first quarter earnings surprise and record Water Transmission Systems backlog have coincided with a sharp 30 day share price return of 29.59% and a year to date share price return of 80.12%. The 1 year total shareholder return of...

In early May 2026, AbbVie reported that shareholders voted against a proposal to require an independent board chair while the company highlighted extensive new real‑world and long‑term data for its key immunology drugs SKYRIZI and RINVOQ in inflammatory bowel disease. The combination of fresh efficacy and quality‑of‑life data for these therapies and continued conference outreach underscores how central immunology remains to AbbVie’s business profile. We’ll now examine how AbbVie’s latest...

Soft earnings didn't appear to concern Park-Ohio Holdings Corp.'s ( NASDAQ:PKOH ) shareholders over the last week. Our...

Investors may be wondering whether Colgate-Palmolive stock is offering fair value at current levels, or if the price is already reflecting too much optimism. The stock last closed at US$88.84, with returns of 1.7% over the past week, 5.6% over the past month, 14.4% year to date, 1.6% over 1 year, 19.7% over 3 years and 19.0% over 5 years. This gives a snapshot of how the market has been pricing the company recently. Recent news around Colgate-Palmolive has focused on its position within the...

World Kinect (WKC) has returned to focus after Q1 results reflected stronger profits in its marine and aviation segments, alongside a $75 million share repurchase and a higher full-year 2026 adjusted EPS outlook. See our latest analysis for World Kinect. The Q1 beat and higher 2026 guidance appear to be feeding into price momentum, with a 1 month share price return of 20.19% and a year to date share price return of 16.25% against a more modest 1 year total shareholder return of 4.90%. This...

The market wasn't impressed with the soft earnings from Murphy Oil Corporation ( NYSE:MUR ) recently. Our analysis has...

Wondering if GE Vernova at US$1,090.53 is still offering value after a strong run, or if you are turning up late to the story. The stock has logged returns of 4.3% over the past week, 10.4% over the past month, 60.5% year to date and 156.0% over the last year, which naturally raises questions about how the current price lines up with underlying value. Recent coverage has focused on GE Vernova as a pure play in the capital goods space following its separation from General Electric, with...

The market was pleased with the recent earnings report from Open Text Corporation ( NASDAQ:OTEX ), despite the profit...

Recent performance snapshot T. Rowe Price Group (TROW) has recently drawn investor attention after a period where the stock is up about 7% over the past month and roughly 9% in the past 3 months. See our latest analysis for T. Rowe Price Group. At a share price of $102.41, T. Rowe Price Group has a 30 day share price return of 6.86% and a 1 year total shareholder return of 10.54%. This suggests recent momentum contrasts with weaker longer term results such as the 5 year total shareholder...

In early May 2026, BridgeBio Pharma reported strong new clinical and regulatory progress, including FDA submission of encaleret for ADH1 and additional Phase 3 data for acoramidis (Attruby/BEYONTTRA) in transthyretin amyloid cardiomyopathy, alongside higher quarterly revenue and a newly authorized US$500,000,000 share repurchase program. The combination of compelling late-stage trial readouts, expanding global approvals for acoramidis, and an NDA for encaleret underscores BridgeBio’s push to...

The market for Dine Brands Global, Inc.'s ( NYSE:DIN ) shares didn't move much after it posted weak earnings recently...

Eaton (ETN) is back in focus after strong first quarter results, updated earnings guidance, and a series of AI focused power infrastructure moves that include a new US$30 million switchgear facility in Nebraska. See our latest analysis for Eaton. The stock has kept its recent momentum going, with a year to date share price return of 24.68% and a 5 year total shareholder return of 207.68%. Eaton's AI centric power projects, Boyd Thermal acquisition and NVIDIA partnership keep it firmly on...

Nu Holdings (NYSE:NU) is back in focus after first quarter 2026 results combined strong reported revenue and net income with misses versus earnings and sales forecasts, alongside fresh progress on AI and U.S. expansion. See our latest analysis for Nu Holdings. At a share price of US$12.93, Nu’s recent momentum has cooled, with the 30 day share price return down 15.77% and the year to date share price return down 24.03%. Even so, the 3 year total shareholder return of 102.35% still reflects a...

In the first quarter of 2026, Arbor Realty Trust, Inc. reported sales of US$8.06 million, net income of US$10.97 million, and a US$12.50 million impairment loss on real estate owned, while also declaring a reduced quarterly dividend of US$0.17 per share. The combination of lower earnings, sizeable impairment charges, and another dividend reset underscores how prolonged troubles in non-performing loans and real estate owned are pressuring Arbor Realty Trust’s balance sheet and income...